RxDoctor Payments DataLook up a doctor →

Angela Dispenzieri, MD

Hematology · Rochester, MNNPI 1235115023

Payments from drug & device makers

$3,321,490in general payments, 2019–2025

Across 207 payments — averaging $16,046 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.3M
  • AstraZeneca$1.3M
  • Takeda Pharmaceuticals U.S.A., Inc.$407K
  • Alnylam Pharmaceuticals Inc.$173K
  • AbbVie$137K
  • Bristol Myers Squibb$29K
  • plus $52K from 9 others
$311,252in research payments, 2019–2025

Across 48 payments — averaging $6484.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$153K
  • Janssen Research & Development, LLC$63K
  • Pfizer$55K
  • Recordati_rare_diseases_inc.$40K
  • Bristol Myers Squibb$476

What the payments were for

  • Consulting fees$56,84665%
  • Speaking & faculty fees$4,9206%
  • Travel & lodging$21,92525%
  • Food & beverage$2,3293%
  • Education$1,4472%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,321,490 in reported general payments places this provider in the 90th percentile of 111 hematology providers in Minnesota.

See all hematology providers in Minnesota

Medicare billing

Part B allowed, 2024
$200,382
Medicare patients
266
Services billed
10,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide52$904,440
VenclextaVenetoclax21$471,561
Lenalidomide27$373,905
EliquisApixaban14$9,214
CholestyramineCholestyramine (With Sugar)12$1,690
Acyclovir64$1,316
SynthroidLevothyroxine Sodium12$1,142
Gabapentin34$714
Duloxetine Hcl15$454
Dexamethasone29$334
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$278
Amlodipine Besylate12$139
Oxycodone Hcl12$133
Tramadol Hcl11$87
Zolpidem Tartrate15$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$29,221$904,44052 claims
AbbVieVenclexta, Synthroid$136,560$472,70333 claims
PfizerEliquis$1,261,667$9,21414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 hematology providers in Minnesota.

Other hematology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →